Settling GSK breakup
Adaptimmune announced additional details regarding the terms for the transfer of PRAME and NY-ESO-1 programs from GSK. Adaptimmune gained back the rights for lete-cel (NY-ESO-1-targeting TCR T therapy), next-generation NYESO CD8 and NYESO TGF, as well as preclinical PRAME-targeting programs followi
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.